Please assess the completion status of the following clinical trial:

Trial Title: Apixaban for the Prevention of Venous Thromboembolism in Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* A newly diagnosed cancer site or progression of the malignant disease after complete or partial remission.~* Initiating a new course of chemotherapy with a minimum intent of 3 months therapy~* A VTE risk stratification score of ≥ 2, according to the scoring method~* Age 18 years old or older~* Provide written informed consent~Exclusion Criteria:~* Lesions or conditions at increased risk of clinically significant bleeding (eg. active peptic ulcer disease)~* Objectively confirmed substantial liver insufficiency as defined by clinical manifestations of ascites, cirrhosis, encephalopathy and/or jaundice and/or biochemical abnormalities in liver function tests including hypoalbuminemia (\< 3.5 gr/dL), elevated levels of total bilirubin (\> 25 umol/L), elevated liver transaminases (2 times the upper limit of normal) and/or biochemical diagnosis of biliary tract obstruction (elevated levels of gamma-glutamyl transferase and alkaline phosphatase, 3 times the upper limit of normal). \*~* Diagnosis of basal cell or squamous cell carcinoma of the skin or acute leukemia or myelodysplastic syndrome\*\*~* Planned stem cell transplant~* Life expectancy less than 6 months~* Acute or chronic renal insufficiency with glomerular filtration rate (GFR) \< 30 ml/min calculated by the Cockroft and Gault formula.~* Pregnancy\*\*\*~* Continuous anticoagulation with vitamin K antagonists, low-molecular-weight heparin (LMWH), or other oral anticoagulants~* Weight \< 40 Kg~* Platelet count \< 50 x 109/L~* Known allergies to ingredients contained in apixaban~* Use of any contraindicated medications with apixaban

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Apixaban (Type: ACTIVE_COMPARATOR): 2.5 mg BID for 6 months
- Placebo drug (Type: PLACEBO_COMPARATOR): 2.5 mg BID for 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).